文献速递艾滋病与性传播感染

基线PI敏感性对尼日利亚HIV-1二线PI方案病毒学抑制的影响

Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

在尼日利亚开展的一项配对病例对照研究,对接受基于利托那韦增效蛋白酶抑制剂的二线抗逆转录病毒治疗(ART)的患者进行Gag-蛋白酶表型敏感性检测。病毒学失败者与成功者的洛匹那韦IC50倍数变化无显著差异(中位数4.04 vs 4.13,P=0.94)。基线Gag-蛋白酶介导的表型敏感性对二线PI-based ART的病毒学结局无影响。

要点

  • 基线Gag-蛋白酶表型PI敏感性未预测二线PI-based ART的病毒学失败。
  • 洛匹那韦IC50倍数变化在失败与成功组间无统计学差异。
  • 单例基线FC>10者后续使用利托那韦增效洛匹那韦失败。

核心结论

  • 在尼日利亚人群中,基线HIV-1 Gag-蛋白酶衍生的表型PI敏感性对基于PI的二线ART病毒学结局无显著影响。

研究设计与样本

  • 研究纳入经历二线利托那韦增效PI-based ART失败者,按亚型、性别、年龄、病毒载量、治疗时长和基线CD4计数与病毒学成功者配对。
  • 成功定义为第48周HIV-1 RNA病毒载量<400拷贝/mL,从患者样本扩增全长Gag-蛋白酶进行体外表型敏感性检测,以IC50倍数变化(FC)相对于B亚型参考株表示。

主要发现

  • 洛匹那韦IC50 FC中位数(IQR)在病毒学失败者为4.04(2.49-7.89),在病毒学成功者为4.13(3.14-8.17),P=0.94。
  • 1例患者基线洛匹那韦FC>10,后续以利托那韦增效洛匹那韦为PI方案时发生病毒学失败。
  • 两组单轮复制效率无统计学显著差异(P=0.93),单轮复制效率与洛匹那韦FC呈中度相关(相关系数0.32)。

关键数值与推荐

  • 病毒学成功定义为第48周HIV-1 RNA<400拷贝/mL。
  • PI敏感性以IC50倍数变化(FC)相对于B亚型参考株表示。

临床怎么用

  • 在CRF02_AG/G亚型为主的地区,基线Gag-蛋白酶表型PI敏感性检测结果不应单独用于指导二线PI-based ART方案选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Previous work showed that gag-protease-derived phenotypic susceptibility to PIs differed between HIV-1 subtype CRF02_AG/subtype G-infected patients who went on to successfully suppress viral replication versus those who experienced virological failure of lopinavir/ritonavir monotherapy as first-line treatment in a clinical trial. We analysed the relationship between PI susceptibility and outcome of second-line ART in Nigeria, where subtypes CRF02_AG/G dominate the epidemic. METHODS: Individuals who experienced second-line failure with ritonavir-boosted PI-based ART were matched (by subtype, sex, age, viral load, duration of treatment and baseline CD4 count) to those who achieved virological response ('successes'). Successes were defined by viral load <400 copies of HIV-1 RNA/mL by week 48. Full-length Gag-protease was amplified from patient samples for in vitro phenotypic susceptibility testing, with PI susceptibility expressed as IC50 fold change (FC) relative to a subtype B reference strain. RESULTS: The median (IQR) lopinavir IC50 FC was 4.04 (2.49-7.89) for virological failures and 4.13 (3.14-8.17) for virological successes (P = 0.94). One patient had an FC >10 for lopinavir at baseline and experienced subsequent virological failure with ritonavir-boosted lopinavir as the PI. There was no statistically significant difference in single-round replication efficiency between the two groups (P = 0.93). There was a moderate correlation between single-round replication efficiency and FC for lopinavir (correlation coefficient 0.32). CONCLUSIONS: We found no impact of baseline HIV-1 Gag-protease-derived phenotypic susceptibility on outcomes of PI-based second-line ART in Nigeria.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Datir R, El Bouzidi K, Dakum P, et al. Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria. J Antimicrob Chemother. 2019. PMID: 30726945. doi:10.1093/jac/dkz005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。